Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data.

Breast cancer research : BCR - 23 Jan 2014

Zardavas Dimitrios, Phillips Wayne A, Loi Sherene

Abstract excerpt

PIK3CA mutations represent one of the most common genetic aberrations in breast cancer. They have been reported to be present in over one-third of cases, with enrichment in the luminal and in human epidermal growth factor receptor 2-positive subtypes. Substantial preclinical data on the oncogenic properties of these mutations have been reported. However, whilst the preclinical data have clearly shown an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Class I Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Phosphatidylinositol 3-Kinases

Share to Proto-Oncogene Proteins c-akt

Share to Receptor, ErbB-2

Share to TOR Serine-Threonine Kinases

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 25192370
DOI: 10.1186/bcr3605
PMCID: PMC4054885

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data.PMID 25192370Read ↗

PIK3CA/AKT1 Mutations in Breast Carcinoma: a Comprehensive Review of Experimental and Clinical StudiesSemantic proximity Read ↗

Genetically engineered mouse models of PI3K signaling in breast cancerSemantic proximity Read ↗

PI3K mutations in breast cancer: prognostic and therapeutic implicationsSemantic proximity Read ↗

The PIK3CA gene as a mutated target for cancer therapy.Semantic proximity Read ↗

Inhibitors of STAT3, β-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors.Semantic proximity Read ↗

Conditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations.Semantic proximity Read ↗

[Clinical, diagnostic significance and theranostic interest of PIK3CA gene mutations in breast cancer].Semantic proximity Read ↗

Expression of PIK3CA mutant E545K in the mammary gland induces heterogeneous tumors but is less potent than mutant H1047RSemantic proximity Read ↗

Elevated PI3K signaling drives multiple Breast Cancer subtypesSemantic proximity Read ↗

PIK3CA-mutations in breast cancer.Semantic proximity Read ↗

Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapiesSemantic proximity Read ↗

The Effect and Treatment of PIK3CA Mutations in Breast Cancer: Current Understanding and Future DirectionsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.